At ReiThera, we believe in pushing the boundaries of science in search of breakthroughs. Our scientists are working on groundbreaking projects with the purpose of empowering adenovirus vector technology, and creating novel and important vaccines.
The adenovirus vector platform aims to generate a pipeline of genetic vaccines against a range of diseases, for which no effective vaccines currently exist.
Our scientists have obtained excellent efficacy data from preclinical models and in clinical programs. The adenovirus vectors can be developed in compliance with the most stringent regulatory requirements.
Over 4,000 subjects (including elderly people, infants and chronically-infected hepatitis C and HIV patients) have been vaccinated to date with chimpanzee adenovirus vectors developed by our scientists. This research has shown the excellent T- and B-cell immunity of these adenovirus vectors, as well as good safety and tolerability profiles.
In extensive studies, adenovirus has been found to be one of the most potent vectors for the induction of CD8 T-cell responses in non-human primates and in humans, while also inducing protective antibody responses.
In large clinical trials, replication-defective adenovirus-based vaccines have been shown to have good safety profiles in humans. Adenovirus possesses a number of desirable properties, including the ability to infect replicating and non-replicating cells, broad tissue tropism, the ability to efficiently express long stretches of inserted genes, ease of propagation in cell culture to high titers, and an inexpensive manufacturing process.
In addition to high immunological potency, an effective vaccine requires high productivity (growth in cell lines) and low seroprevalence (pre-existing neutralizing antibodies against the adenovirus vector). Human adenovirus vectors suffer from the serious drawback of being neutralized by pre-existing antibodies in people.
A broad range of adenovirus vector strains from non-human primates have been isolated and extensively characterized by our scientists. These vectors are structurally similar to human adenoviruses but serologically distinct, and therefore not neutralized by antibodies present in humans.
By conducting thorough in vitro and in vivo analyses, we are pursuing the identification of the best vaccine vector candidates, which bring together crucial features such as: i) strong immunological potency, ii) the ability to be produced in human cell lines approved by regulatory agencies, and iii) good safety profile.
Our efforts are focused on exploring the versatile adenovirus vector technology in the discovery and development of a pipeline of next-generation genetic vaccines against a range of infectious diseases.
We have also developed packaging cell lines and manufacturing processes, creating a robust platform to support the development and commercialization of our vaccines.